In 2018, the US Food and Drug Administration approved the first oral, selective BCL-2 inhibitor (venetoclax) for use in combination with HMAs in newly diagnosed AML patients aged ≥75 years and unfit for IC. Here, BCL2 is linked to acute myeloid leukemia.